This groundbreaking company specializes in developing oligonucleotide immunotherapies to combat treatment-resistant and metastatic cancers. Their lead drug candidate, OLIM-01, specifically targets genitourinary and head and neck cancers. By activating dormant immune cells within the tumor microenvironment, Olimmune's therapeutic drug empowers cancer patients to regulate their immune system and effectively fight against the disease.